Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Invested Capital (2016 - 2025)

Historic Invested Capital for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $492.3 million.

  • Myriad Genetics' Invested Capital fell 3620.58% to $492.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $492.3 million, marking a year-over-year decrease of 3620.58%. This contributed to the annual value of $740.7 million for FY2024, which is 985.76% down from last year.
  • Myriad Genetics' Invested Capital amounted to $492.3 million in Q3 2025, which was down 3620.58% from $447.5 million recorded in Q2 2025.
  • Myriad Genetics' Invested Capital's 5-year high stood at $1.0 billion during Q1 2021, with a 5-year trough of $447.5 million in Q2 2025.
  • Over the past 5 years, Myriad Genetics' median Invested Capital value was $821.7 million (recorded in 2023), while the average stood at $822.3 million.
  • In the last 5 years, Myriad Genetics' Invested Capital skyrocketed by 667.68% in 2024 and then tumbled by 4266.5% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Invested Capital stood at $967.8 million in 2021, then decreased by 8.47% to $885.8 million in 2022, then decreased by 7.24% to $821.7 million in 2023, then decreased by 9.86% to $740.7 million in 2024, then plummeted by 33.54% to $492.3 million in 2025.
  • Its last three reported values are $492.3 million in Q3 2025, $447.5 million for Q2 2025, and $764.2 million during Q1 2025.